Versant Venture Capital VI, L.P.'s Net Worth
Estimate Recalculated Nov 11, 2024 01:47PM EST
Who is Versant Venture Capital VI, L.P.
Versant Venture Capital VI, L.P. has an estimated net worth of $233 Million. This is based on reported shares across multiple companies, which include LENZ Therapeutics, Inc., Repare Therapeutics Inc., Monte Rosa Therapeutics, Inc., Century Therapeutics, Inc., Oyster Point Pharma, Inc., Akero Therapeutics, Inc., Aligos Therapeutics, Inc., Tempest Therapeutics, Inc., Pandion Therapeutics Holdco LLC, Passage BIO, Inc., Black Diamond Therapeutics, Inc., and Contineum Therapeutics, Inc..
SEC CIK
Versant Venture Capital VI, L.P.'s CIK is 0001687880
Past Insider Trading and Trends
2020 was Versant Venture Capital VI, L.P.'s most active year for acquiring shares with 10 total transactions. Versant Venture Capital VI, L.P.'s most active month to acquire stocks was the month of May. 2020 was Versant Venture Capital VI, L.P.'s most active year for disposing of shares, totalling 48 transactions. Versant Venture Capital VI, L.P.'s most active month to dispose stocks was the month of October. 2020 saw Versant Venture Capital VI, L.P. paying a total of $7,525,558.00 for 16,110,648 shares, this is the most they've acquired in one year. In 2019 Versant Venture Capital VI, L.P. cashed out on 14,663,947 shares for a total of $20,081,962.66, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
